News

Align Technology shares rise after Q2 earnings and revenues beat estimates, fueled by record Clear Aligner shipments and wider non-GAAP margins.

ISRG pairs durable platform demand and higher margin guidance with caution on softer U.S. procedure growth and deferred care.

At first glance, its numbers were impressive.

ISRG beats second-quarter earnings and revenue estimates, but shares fall after hours as procedure growth slows sequentially despite strong placements.

All three major US stock indexes were down Friday, as chipmakers led the way down on the final tradi

Intuitive Surgical (NASDAQ: ISRG) shares fell about 11% on Friday after the robotic surgery company reported second-quarter results that topped Wall Street expectations but disappointed investors with slower US procedure growth and a cautious full-year outlook. The company reported second...

Intuitive Surgical Inc. (NASDAQ:ISRG) shares fell sharply after the medical technology company released second-quarter results that topped Wall Street forecasts but issued a full-year procedure growth outlook that failed to meet investor expectations.

Although the revenue and EPS for Intuitive Surgical (ISRG) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Moby summary of Intuitive Surgical, Inc.'s Q2 2026 earnings call

Intuitive Surgical (NASDAQ:ISRG) reported a solid second quarter of 2026, with management pointing to continued global adoption of its da Vinci, da Vinci SP and Ion platforms, even as U.S. procedure growth moderated and China remained challenging. Chief Executive Officer Dave Rosa said total proced

Intuitive Surgical (ISRG) delivered earnings and revenue surprises of +12.90% and +3.08%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Johnson & Johnson's post-earnings pullback follows a revenue and EPS beat, raised guidance, and analyst price target increases, with talc litigation remaining the key risk to watch.

The robotic surgery company has posted earnings beats in its past four quarters. Can it make it five in a row?

Medical technology company Intuitive Surgical (NASDAQ:ISRG) will be reporting results this Thursday afternoon. Here’s what investors should know.

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the surgical equipment & consumables - specialty industry, including Intuitive Surgical (NASDAQ:ISRG) and its peers.

Intuitive Surgical is approaching a pivotal earnings update as strong forecasts square off against a stock that has lost its footing.

Intuitive Surgical (ISRG) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Shares of Medtronic jumped 5% Wednesday after the medical-device maker reported better-than-expected quarterly results, helped by strong sales of devices used in heart procedures. The company also said it applied for U.

The medical device maker posts fiscal fourth-quarter earnings and revenue that narrowly beat analysts’ estimates.

Intuitive Surgical (ISRG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Becton, Dickinson and Company (NYSE:BDX) reported fiscal second-quarter revenue and adjusted earnings ahead of its internal expectations, while management raised its full-year adjusted earnings outlook and said growth was broad-based across most of the portfolio. Chairman, Chief Executive Officer a

R. Jeffrey Bailly: Thank you, Ron, and thank you to everyone joining the call. UFP had a strong second quarter. Revenue from our two largest customers, Intuitive Surgical and Stryker, grew 10% and 567%, respectively.

Intuitive Surgical’s first quarter results for 2026 exceeded Wall Street’s expectations, with management crediting the outcome to strong global procedure growth and expansion of the da Vinci and Ion platforms. CEO David Rosa pointed to a 17% increase in total procedures, including “broad-based adoption across da Vinci and Ion as customers continue to advance minimally invasive care.” The company also highlighted notable gains in after-hours and non-urology procedures, as well as expanding uptake